🇺🇸 Abrilada in United States

FDA authorised Abrilada on 15 November 2019

Marketing authorisation

FDA — authorised 15 November 2019

Application: BLA761118
Marketing authorisation holder: PFIZER INC
Local brand name: ABRILADA
Indication: INJECTABLE — INJECTION
Status: approved

The FDA approved Abrilada, a biosimilar to adalimumab, on April 30, 2024. Abrilada is a recombinant human immunoglobulin G1 monoclonal antibody that inhibits tumor necrosis factor-alpha. It is indicated for the treatment of several conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis, as stated in the labeling.

Read official source →

Abrilada in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Abrilada approved in United States?

Yes. FDA authorised it on 15 November 2019.

Who is the marketing authorisation holder for Abrilada in United States?

PFIZER INC holds the US marketing authorisation.